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The objective of this study is to determine the in vitro susceptibility of Georgian
bacteriophage cocktails on multidrug resistant (MDR) extended-spectrum beta-
lactamase producing Escherichia coli (ESBL-EC) isolated from patients’ blood and
urine cultures. A total of 615 E. coli isolates were included in this study. Phene
Plate (PhP)-typing and phylogenetic grouping were used for the typing. Antimicrobial
resistance profiles and ESBL production of all isolates were confirmed according
to Clinical and Laboratory Standards Institute (CLSI) criteria. The activities of four
bacteriophage cocktails (Enko-phage, SES-bacteriophage, Pyo-bacteriophage, and
Intesti-bacteriophage) were determined against 142 ESBL-EC using in vitro spot tests.
According to this, Enko-phage were active against 87.3% of the tested strains while that
ratio was 81.7% for Intesti-bacteriophage, 81.7% for Pyo-bacteriophage, and 59.2% for
SES-bacteriophage cocktails. Based on the contingency tests, the phage cocktails were
observed to be statistically significantly (p < 0.001) more effective on ESBL-EC strains
belonging to phylogenetic groups D and B2. The employed phage cocktails were found
to be affective against all tested resistant types. These results are promising especially
for the infections that are caused by MDR pathogens that are difficult to treat. As this
is a preliminary step to the potential clinical trials to be designed for the country, in vitro
confirmation of their success on a MDR ESBL-EC collection should be accepted as an
initial action, which is encouraging to consider clinical trials of phage therapy especially
in countries which are not introduce phage therapy.
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INTRODUCTION
Escherichia coli is the leading bacterial pathogens responsible for intestinal and extraintestinal
infections, including urinary tract infections, bacteremia, and meningitis (Kaper et al., 2004).
Certain strains of E. coli have been shown to carry certain genes coding for enzymes that hydrolyze
a wide range of beta-lactams and are referred to as extended-spectrum beta-lactamase producing
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E. coli (ESBL-EC). In recent years, the dissemination of
ESBL-EC has become a serious health problem worldwide
including Turkey (Pitout and Laupland, 2008; Rodriguez-Bano
and Pascual, 2008; Tasbakan-Isikgoz et al., 2011; Hawser et al.,
2012). ESBL producing pathogens are known to be resistant
not only first, second, and third generation cephalosporins and
monobactams, but also to several other classes of antibiotics.
As a result, infections that are difficult to treat occur, and
occasionally the use of “antibiotics of the last resort” such as
carbapenems, colistin is inevitable (Cantón et al., 2012). However,
unfortunately, emergence of resistance against these drugs of last
resort is also observed around the world (Schwaber and Carmeli,
2008; Hasman et al., 2015). The upcoming threat of increase in
the prevalence of untreatable infections has motivated the quest
for alternatives of antibiotic therapy.
Bacteriophages (phages) are natural parasites of bacteria
and they have been considered as effective agents for the
treatment of bacterial infections since 1920s (Sulakvelidze et al.,
2001; D’Herelle, 2007). The reason phages have been used as
antimicrobial agents in that they can recognize, bind onto, and
reproduce within a bacterial host, resulting in rapid cell lysis.
However, poor understanding of phage biology and inconsistent
outcomes experienced in early trials resulted in the phage therapy
never being adopted universally (Sulakvelidze et al., 2001; Kutter
et al., 2010). The advancement and consequently widespread
use of antibiotics left phage therapy remaining as a common
practice confined in the former Iron Curtain Countries where
it has been successfully applied for around 90 years. Currently,
although antibiotic therapy is successful in the treatment of
majority of infections, frontline therapies are not effective in
noticeable amount exceptions (Gould, 2009; Gootz, 2010; Keske
et al., 2014) which is the underlying reason for the revitalization
of phage therapy in bacterial infections around the world
(Parracho et al., 2012). Thus, adopting this renewed approach
we designed this preliminary study on ESBL-EC since it is
a significant infection control and treatment challenge in the
world.
This study aimed to examine the in vitro activity of Georgian
bacteriophage cocktails which are used as part of standard clinical
practice in the Republic of Georgia on a well-characterized ESBL-
EC isolated from Turkish patients’ blood and urine. As this is
a first step to the potential clinical trials to be designed for the
countries that have reached a very high prevalence country wide,
the study is of capital importance.
MATERIALS AND METHODS
Sample Collection
Clinical samples belonging to five experimental groups were
included in this study. Experimental groups are (i) the blood
of hospitalized patients, (ii) the urine of hospitalized adult
patients, (iii) the urine of hospitalized pediatric patients, (iv)
the urine of adult outpatients, and (v) the urine of pediatric
outpatients. All samples are collected from the patients attending
a 1300-bed tertiary hospital in Kayseri, Turkey, between 2014
and 2016. The samples did not include descriptive information
from any patients. Identification of E. coli strains was performed
using conventional microbiological methods and VITEK-2
(bioMérieux) automated system. Extraction of chromosomal
DNA was done by growing a single colony of the isolates in Luria–
Bertani (LB) broth overnight, collecting pellet in 100 ml sterile
Milli-Q water, and boiling at 95◦C for 15 min. E. coli strains were
subjected to confirmatory tests using PCR amplification of the
universal stress protein (uspA) gene as previously described by
Chen and Griffiths (1998).
Typing of Isolates
Phene Plate (PhP) Fingerprinting
All strains were typed using a high-resolution biochemical
fingerprinting method specifically developed for E. coli strains
(PhPlate AB, Stockholm, Sweden; Landgren et al., 2005).
Inoculation of the plates was done according to the manual
instruction and the plates were incubated at 37◦C. The rate
of each reaction was evaluated by measuring the absorbance
value in each well after 7, 24, and 48 h of incubation
using a digital scanner. After the final scan, the PhPlate
software was used to create absorbance (A620) data from
the scanned plate images and the mean absorbance in each
well over the three readings was calculated, yielding the
biochemical fingerprint for each isolate. The biochemical
fingerprints of the isolates were compared pairwise and
the similarities among the isolates were calculated by the
correlation (similarity) coefficient and clustered according to
the unweighted pair group method with arithmetic averages
(Sneath and Sokal, 1973; Saeedi et al., 2005). Isolate pairs
having a similarity coefficient above the default identity level
(0.975) of software was regarded as identical and assigned to
the same biochemical phenotype. All data handling, including
calculations of correlations and coefficients as well as clustering
were performed using the PhPlate software version 4002 (PhPlate
AB, Stockholm, Sweden).
Phylogenetic Grouping
Phylogenetic grouping (A, B1, B2, D) was done for ESBL-EC
strains using multiplex PCR with primers coding for chuA and
yjaA genes and the DNA fragment TSPE4.C2 according to
Clermont et al. (2000).
Strains belonging to the same biochemical phenotype and
phylogenetic groups were considered as members of the same
clone and were regarded as common types, and those differing
by one method were regarded as single types.
Phenotypic ESBL Detection and
Antimicrobial Resistance Test
ESBL production of the isolates was screened by the double-disk
synergy on Mueller-Hinton agar using cefotaxime, ceftazidime,
cefpodoxime, and ceftriaxone with and without clavulanic acid
(10 mg), according to Clinical and Laboratory Standards Institute
(CLSI), recommendations (Clinical and Laboratory Standards
Institute [CLSI], 2015). After phenotypic confirmation, the
susceptibility of ESBL-EC producing strains was tested
against nine antimicrobial agents using Kirby–Bauer disk
diffusion methods according to CLSI guidelines. Antimicrobial
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agents included were ampicillin/sulbactam, ciprofloxacin,
gentamicin, sulfamethoxazole, amoxicillin/clavulanate,
piperacillin/tazobactam, amikacin, cefepime, imipenem, and
ertapenem. E. coli ATCC 25922 and ESBL-positive
blactx−m−15 ESBL-producing strains were used as quality
control strains.
In vitro Susceptibilities of Bacteriophage
Cocktails
Among all ESBL-EC, one representative from each PhP-
common type and all single types are included in phage
assay. Spot tests were performed to determine the activities
of four commercially available bacteriophage cocktails on
each non-replicating ESBL-EC isolate. The bacteriophage
cocktails produced in the George Eliava Institute and they
were commercially available in sterile media containing
1 × 105−6 phage particles in 1 mL for Pyo-bacteriophage
and Intesti-bacteriophage in Georgia. For the remaining two
cocktails, the plaque forming unit/mL concentration is not
available.
For spot test, all ESBL-EC isolates were initially tested for
their purity on MacConkey agar no. 3. One single colony
were transferred onto LB agar and incubated at 37◦ for 18 h.
These steps were repeated twice to yield desired colonies (i.e.,
round shaped) with similar morphology in the agar plates.
Single colonies were picked and incubated in LB broth for
about 3 h. Then, 100 µL of the bacterial culture (A600 ca.
0.5) mixed with 5 ml of the molten semi-solid LB agar (0.6%)
and over laid on the surface of the LB agar. After 10 min,
10 µL of phage suspension was applied on the bacterial layer
and incubated at 37◦C overnight. Bacterial sensitivity to phage
preparations was established by lysis at the spot where the
phage was deposited (Gabrilovich, 1973). Observing confluent,
semi-confluent, opaque lysis or individual plaques determined
the isolate susceptibility. When the lysis was not possible, the
corresponding isolates were determined to be resistant. Each test
was repeated thrice.
The following four commercial phage cocktails were included
in this study.
Enko-phage active against Salmonella typhimurium,
Salmonella enteritidis, Salmonella heidelberg, Salmonella newport,
Salmonella cholerae, Salmonella oranienburg, Salmonella dublin,
and Salmonella anatum; Shigella flexneri (serovars 1, 2, 3, 4)
and Shigella sonnei (six different serovars), enteropathogenic
E. coli, Staphylococcus aureus, Staphylococcus epidermidis, and
Staphylococcus saprophyticus.
SES-bacteriophage active against Staphylococci (S. aureus,
S. epidermidis, and S. saprophyticus); Streptococci (Streptococcus
pyogenes, Streptococcus sanguis, Streptococcus salivarius, and
Streptococcus agalactiae) and different serotypes of entero-
pathogenic E. coli serovars.
Pyo-bacteriophage active against Staphylococcus spp.,
Streptococcus spp, Pseudomonas aeruginosa, Proteus mirabilis,
Proteus vulgaris, and E. coli.
Intesti-bacteriophage active against Shigella spp., Salmonella
spp., E. coli, Staphylococcus spp., Enterococcus spp., Proteus spp.,
P. aeruginosa.
RESULTS
A total of 615 E. coli were isolated from urine (n = 433) and
blood (n = 182) cultures of patients (one isolate per patient)
included in each experimental group (Table 1). One hundred
and seventy-five out of 615 E. coli strains were confirmed to be
genuine ESBL producers. All 175 ESBL-EC isolates were grouped
into 20 common types (i.e., types with more than two identical
isolates) and 122 single types based on typing methods. The
lowest number of identical isolates in a common type was 2, and
the highest number of identical isolates belonging to a common
type was 5. With the consideration of clonality the number of
representative isolates was determined to be 142 for ESBL-EC.
Phylogenetic distribution of these 142 strains revealed that, 40.8%
of the isolates belonged to group D, 38.1% belonged to B2, 14.2%
belonged to group A, and 7% belonged to B1.
The rates of ESBL-EC within each experimental group were
found to be ranging between 14.7% (for urine culture of
children outpatients) and 40.4% (for blood culture of hospitalized
patients) (Table 2). In addition to ESBL production all isolates
were found to be multidrug resistant (MDR, resistant to >3
classes; Magiorakos et al., 2012; Table 3).The rate of Carbapenem
non-susceptible (non-S) strains was found to be ranging between
2.2 and 5.1% among different experimental groups of ESBL-EC.
All 142 non-replicating ESBL-EC were included in the
bacteriophage assay. According to phage susceptibility assay 131
(92.3%) of the ESBL-EC strains were determined to be susceptible
to at least one phage cocktail. Among those, Enko-phage, Intesti-
bacteriophage, and Pyo-bacteriophage preparations were active
against greater number of isolates than SES-bacteriophage (87.3,
81.7, 81.7, and 59.2%, respectively). Resistance and sensitivity
profiles of these four phage preparations are given in Table 4.
Considering the phage susceptibility distributions of the tested
strains with respect to different phylogenetic groups, it was
observed that each phylogenetic group shows different phage
susceptibility characteristics. While Enko, Pyo, and Intesti phages
are dominantly effective on B2 and D phylogenetic groups (7.4%
resistance rate for all phage cocktails in B2, 3.4, 5.2, and 8.6%
resistance rates for Enko, Pyo, and Intesti, respectively in D), a
more even susceptibility response can be observed for A and B1
TABLE 1 | Numbers of confirmed E. coli strains included in this study
within each experimental group.
Experimental groups Number of E. coli strains
ESBL −ve ESBL +ve Total
Urine
Hospitalized adults 74 43 117
Hospitalized children 26 19 45
Adult outpatients 92 26 118
Children outpatients 131 22 153
Blood (adults and children) 117 65 182
Total 440 175 615
ESBL −ve, strains not producing extended-spectrum beta-lactamases; ESBL +ve,
strains producing extended-spectrum beta-lactamases.
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TABLE 2 | Distribution of 615 E. coli strains within each experimental group after PhP-typing.
Number of representative strains PhP-types
Experimental groups ESBL −ve ESBL +ve Total %ESBL +ve Common types Single types DI
Urine
Hospitalized adults 65 33 98 33.7 12 (31) 86 0.996
Hospitalized children 23 14 37 37.9 5 (13) 32 0.991
Adult outpatients 70 21 91 23.01 18 (45) 73 0.994
Children outpatients 87 15 102 14.07 25 (76) 77 0.990
Blood 87 59 146 40.4 23 (59) 123 0.996
ESBL −ve, strains not producing extended-spectrum beta-lactamases; ESBL +ve, strains producing extended-spectrum beta-lactamases; DI, diversity index. The
numbers in the bracket indicated how many strains belong to common types.
TABLE 3 | Antimicrobial resistance percentages of 142 ESBL-EC strains.
Experimental groups Antimicrobial agents tested
SAM CIP GEN STX AMC TZP AMK∗ FEP IMI ERT
Urine (83)
Hospitalized patients (47) 82 73.3 42.3 74.5 51.2 30 5 100 2.2 2.2
Outpatients (n = 36) 79.2 60.5 24.4 60.2 47.6 20 0 100 0 0
Blood (n = 59) 95 67.8 48 78 59.5 40.7 3.4 96.6 5.1 3.4
SAM, ampicillin/sulbactam; CIP, ciprofloxacin; GEN, gentamicin; STX, sulfamethoxazole; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; AMK, amikacin; FEP,
cefepime; IMI, imipenem; ERT, ertapenem. ∗Reduce susceptibility.
phylogenetic groups (p < 0.00001, chi-square test). This trend
can also be observed for SES cocktail with statistical significance
(p = 0.000295, chi-square test), yet effectiveness for B2 and D
phylogenetic groups seems to be less than the other cocktails (27.7
and 34.4% resistance rates for B2 and D groups, respectively)
(Table 5).
ESBL-EC strains isolated from hospitalized patients were
more susceptible to Enko-phage than other phage preparations,
whereas outpatients’ isolates were more susceptible to Pyo-
bacteriophage than the other cocktails. Eleven (7.7%) of
the ESBL-EC isolates were found to be resistant to all
commercially available bacteriophage cocktails. These 11 ESBL-
EC were isolated from blood (n = 5), from the urine of
hospitalized adults (n = 2), from the urine of pediatric
outpatients (n = 2) and from the urine of adult outpatients
(n = 2). The susceptibility/non-susceptibility patterns of
E. coli showed no correlation with their antibiotic resistance
patterns.
DISCUSSION
Over the past decade, the prevalence of ESBL-EC has attracted
the attention of health authorities due to their increasing rates
on a daily basis (Paterson and Bonomo, 2005). Recent studies
have shown that the prevalence of ESBL-EC in different countries
can be as high as 63%, with the highest rate belonging to
E. coli isolated from ICU patients in Turkey (Hawser et al.,
2009; Magiorakos et al., 2012; Nakai et al., 2016). Reports
indicated that ESBL-EC rates are generally very high in Turkey;
however, previous studies generally do not take the clonal
TABLE 4 | Sensitivity profiles of tested phage cocktails on 142 ESBL-EC
included in this study.
Number of ESBL-EC strains
ENKO SES PYO INTESTI
Confluent 38 1 38 35
Semi-confluent 29 10 27 20
Opaque lysis 23 7 23 27
Individual plaques 34 66 28 34
Resistant 18 58 26 26
ENKO, Enko-phage; SES, SES-bacteriophage; PYO, Pyo-bacteriophage; INTESTI,
Intesti-bacteriophage.
relationships of the isolates into account (Kacmaz et al., 2005).
Although molecular typing methods such as pulsed field gel
electrophoresis (PFGE) or multilocus sequence typing (MLST)
have been used extensively for determining clonal relationships of
the investigated strains, for practical purposes, we employed the
PhP-typing method that specifically developed to discriminate
E. coli strains (Kühn et al., 1995). This system has been
used in several epidemiological studies (Ahmed et al., 2006;
Cassanovas-Massana and Blanch, 2013) and was shown to
have similar discriminatory power with the genotypic methods
(Ansaruzzaman et al., 2000; Vollmerhausen et al., 2011). Thus,
the ESBL-EC rates (between 14.7 and 40.4%) reported in this
study might be indicating a more accurate estimate for Turkish
outpatients and hospitalized patients. However, the ESBL-EC
ratio especially for hospitalized patients, are still very high
and the required precautions should be taken urgently. In
addition to ESBL production, the high antibiotic resistance
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TABLE 5 | Association between phylogenetic groups and phage resistance
among 142 ESBL-EC strains.
Number of
strains
Number of strains in each
phylogenetic groups
B2 D A B1 p value
ENKO
Resistant 18 4 2 10 2 <0.00001
Susceptible 124 50 56 10 8
SES
Resistant 58 15 20 17 6 0.000295
Susceptible 84 39 38 3 4
PYO
Resistant 26 4 3 14 5 <0.00001
Susceptible 116 50 55 6 5
INTESTI
Resistant 26 4 5 13 5 <0.00001
Susceptible 116 50 53 7 5
ENKO, Enko-phage; SES, SES-bacteriophage; PYO, Pyo-bacteriophage; INTESTI,
Intesti-bacteriophage; p values were calculated using chi-square test.
rates found this study might be attributed to their frequent
preference in empirical treatment and the overall antibiotics
usage policies. A previous Turkish meta-study highlighted the
increase of ciprofloxacin, cefepime, co-trimoxazole resistance
and ESBL production during the study period of 1996–2012
(Aykan and Cifci, 2013). As co-resistance to aminoglycosides
and quinolones is developed quickly during the ESBL-EC
treatments, carbapenems have been the drugs of choice when
an infection is caused by ESBL-EC. In this study carbapenem
resistance ratio was found to be between 2.2 and 5.1%. Since
the carbapenems are still active against the majority of ESBL-
EC, clinicians increasingly prefer carbapenems for empiric
or definitive therapy in community-onset and nosocomial
infections caused by this pathogen (Rodríguez-Bano et al.,
2012). However, this situation results in a frequent explosion
of carbapenems to bacteria, which consequently makes the
spreading of carbapenemase-producing bacteria scenario more
probable and worrisome.
The treatment difficulties on infections caused by MDR
pathogens continue to be a vexing problem. Thus, alternative
approaches as the treatment options are in quest. Being one of
the most popular approaches employing phages as anti-infective
agents was adopted in this study. The results of the study indicate
that, a great majority (131/142, 92.3%) of diverse ESBL-EC strains
were susceptible to at least one phage cocktail. Furthermore,
considering the high diversity among each experimental groups
based on typing methods, it might be concluded that phages
are effective on a broad range of ESBL-EC clones. This is quite
promising especially from the point of infections difficult to
treat that are caused by MDR pathogens. In an Irish study
conducted by Fitzgerald-Hughes et al. (2014), 82% of ESBL-EC
isolated from patients were found to be susceptible to the same
bacteriophage cocktails used in current study. Higher percentage
found in our study might be explained by the geographical
contact between Georgia and Turkey. Because of the neighboring
geographies, residents go back and forth between these two
countries resulting in bacterial transfers. Thus, as the producer
(The G. Eliava Institute of Bacteriophages, Microbiology and
Virology) updates its commercial phages regularly, new phages
against new strains disseminated from Turkey (e.g., via patients,
food, etc.) might find a room in these bacteriophage cocktails.
However, in another study conducted by Sybesma et al. (2016)
in which they used 29 E. coli bacteriophages from the Eliava
collection in addition to four commercial phage cocktails on
E. coli set compromising ESBL negative and positive E. coli,
the phage susceptibility rate was found to be 92.6%. In the
current study, 7.7% ESBL-EC isolates were found to be resistant
to all bacteriophage cocktails tested. Since the phage cocktails
are originated from Georgian biogeography, the phages of these
strains might not be contained in the cocktail preparations. On
the other hand, isolation of bacteriophages, which are able to
be effective on these resistant strains from those pathogens’ own
environment might be possible. With a specified preparation of
phage cocktails and/or with the adaptation of bacteriophages
(Sybesma et al., 2016), even more successful susceptibility results
are potentially achievable. In our study, SES-bacteriophage was
the least active (59.2%) cocktail whereas in Fitzgerald-Hughes
et al.’s (2014) study, SES-bacteriophage was the most active phage
preparation. This outcome might be the indication of different
E. coli sub-groups being common in Ireland and in Turkey.
According to our study, bacteriophage cocktails were found
to be effective against all antimicrobial resistance types tested,
including carbapenem resistance. This orthogonality between
the phage activity and the antimicrobial resistance might be
an encouraging factor for the adoption of phage therapy as
an alternative or complementary option to difficult to treat
infections. For instance, in this study the majority of ESBL-EC
(58.4%) were isolated from the urine cultures of the patients. For
these patients, carbapenems are generally considered as the drug
of choice (Prakash et al., 2009) and in Turkey there are no oral
options for carbapenem treatment. Therefore, treatment for the
urinary tract infections caused by ESBL-EC generally requires
hospitalization due to intravenous antibiotic therapy application.
This is an unfavorable situation as it increases the odds of
the patients’ being exposed to nosocomial infections, as well
as increasing the medical expenses. Considering these multiple
drug resistant pathogens are frequently susceptible to the tested
phages according to our in vitro experiments, employing phage
therapy (oral) with in vitro tested phage preparations could be an
alternative or complementary approach for the cases that narrow
spectrum antibiotic therapy is not sufficient or hospitalization is
required.
The association of the phylogenetic groups with the virulence
characteristics of E. coli has been repeatedly reported in the
literature, which allows a separation of commensal (A and
B1) and pathogenic (B2 and D) strains (Bingen et al., 1998;
Duriez et al., 2001). As B2 and D are mainly accepted to
contain the pathogenic strains, while A and B1 phylogenetic
groups are known to mostly include environmental/commensal
strains, the altering characteristics might reveal a feature for the
employed phage cocktails. According to our results, the cocktails
have a particular effectiveness on the pathogenic strains. The
Frontiers in Microbiology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 1761
fmicb-07-01761 November 1, 2016 Time: 17:2 # 6
Gundogdu et al. Effectiveness of Bacteriophage Cocktails on Clinical ESBL-E. coli
underlying reason for that phenomenon might be an artificial
selection of “pathogen killing” bacteriophages during phage
adaptation procedures since they are selected on clinical strains.
Anyhow, this finding can lead us to draw a conclusion that the
bacteriophage cocktails are highly specific to selected pathogens,
which might turn out to be a preferable feature as they are less
likely to harm beneficial components of human microbiome even
when they are used orally.
Journals published since 1920s have indicated that the success
rate of the in vivo phage therapy—orally, rectally, locally,
intrapleural injections or intravenously, etc.—is nearly 95%,
clinical improvements or full recovery is usually observed within
at most 7 days with no reports of serious complications or
side effects (allergy, kidney or liver failure, etc.) associated
with their use (Chanishvili, 2012). Although clinical practice
of phage therapy as a common medical practice has not been
approved yet, except a few Eastern European countries, some
studies conducted in EU have already reached the clinical trial
phase (Merabishvili et al., 2009; Rhoads et al., 2009; Wright
et al., 2009; Pelfrene et al., 2016). As an example, a study
started in 2013 and conducted within European Union PF7
programme with the collaboration of researchers from Belgium,
France, and Switzerland, achieved their first phage therapy
application of burn wound infections on human patients in July
20151.
CONCLUSION
This study demonstrated the in vitro activity of bacteriophage
preparations that are used as a part of standard clinical practice
in the Republic of Georgia, against MDR ESBL-EC isolated from
Turkish patients. Although bacteriophage therapy has been a
successful part of standard healthcare practice for decades, the
non-practicing camp has been skeptical to accept bacteriophages
as alternative anti-infectives. However, the need for novel
antimicrobial therapies have always been of great importance, yet
with the emergence of pan-resistant Gram-negative pathogens
1 http://www.phagoburn.eu
recently (Arias and Murray, 2009; Glupezynski et al., 2010) it
could be argued that the quest has never been that crucial since
the beginning of the antibiotic era. Thus, in vitro confirmation of
their success on a well-characterized isolate collection is reported
as an initial action, which is encouraging for their clinical use
especially for infections with treatment difficulties. Moreover, the
effectiveness of generic phage cocktails which are not specifically
produced for strains of concern is an implication that the
spectrum of phages is large enough to allow their general use.
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